Core Insights - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases related to dysregulated aldosterone [1][3] - The company will participate in the Bank of America Securities 2025 Health Care Conference from May 12-15, 2025, with a presentation scheduled for May 14, 2025, at 4:35 PM PDT [1][2] Company Overview - Mineralys Therapeutics is developing its initial product candidate, lorundrostat, which is a proprietary, orally administered, highly selective aldosterone synthase inhibitor aimed at treating cardiorenal conditions influenced by dysregulated aldosterone [3] - The company is based in Radnor, Pennsylvania, and was founded by Catalys Pacific [3]